Jefferies Group Analysts Raise Earnings Estimates for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Analysts at Jefferies Group boosted their FY2017 earnings per share (EPS) estimates for Alnylam Pharmaceuticals in a research note issued on Monday, according to Zacks Investment Research. Jefferies Group analyst M. Raycroft now forecasts that the biopharmaceutical company will post earnings of ($5.39) per share for the year, up from their prior forecast of ($5.49). Jefferies Group currently has a “Buy” rating and a $130.00 price target on the stock. Jefferies Group also issued estimates for Alnylam Pharmaceuticals’ Q4 2017 earnings at ($1.32) EPS, FY2018 earnings at ($5.70) EPS, FY2019 earnings at ($3.91) EPS, FY2020 earnings at ($1.71) EPS and FY2021 earnings at $1.41 EPS.

ALNY has been the subject of a number of other reports. Credit Suisse Group lifted their price objective on Alnylam Pharmaceuticals from $123.00 to $151.00 and gave the company an “outperform” rating in a report on Friday, November 3rd. Piper Jaffray Companies reissued an “overweight” rating and set a $14.71 price objective (down from $188.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, November 2nd. B. Riley initiated coverage on Alnylam Pharmaceuticals in a report on Wednesday, November 1st. They set a “buy” rating and a $240.00 price objective for the company. Goldman Sachs Group raised Alnylam Pharmaceuticals from a “buy” rating to a “conviction-buy” rating in a report on Friday, December 15th. Finally, FBR & Co initiated coverage on Alnylam Pharmaceuticals in a report on Monday, October 30th. They set a “buy” rating and a $150.00 price objective for the company. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $121.20.

Alnylam Pharmaceuticals (NASDAQ ALNY) opened at $124.64 on Wednesday. The company has a market capitalization of $12,260.00, a price-to-earnings ratio of -23.74 and a beta of 2.98. Alnylam Pharmaceuticals has a 12-month low of $35.98 and a 12-month high of $147.63. The company has a debt-to-equity ratio of 0.14, a current ratio of 9.83 and a quick ratio of 9.83.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.11). The firm had revenue of $17.10 million during the quarter, compared to the consensus estimate of $28.15 million. Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The firm’s revenue for the quarter was up 24.8% compared to the same quarter last year. During the same period last year, the business earned ($1.21) earnings per share.

In related news, VP Michael Mason sold 36,745 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $131.59, for a total value of $4,835,274.55. Following the completion of the sale, the vice president now directly owns 6,352 shares in the company, valued at $835,859.68. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Laurie Keating sold 6,249 shares of the business’s stock in a transaction dated Wednesday, December 20th. The stock was sold at an average price of $121.20, for a total value of $757,378.80. Following the transaction, the senior vice president now owns 17,749 shares of the company’s stock, valued at $2,151,178.80. The disclosure for this sale can be found here. Over the last quarter, insiders sold 274,075 shares of company stock valued at $35,356,089. Corporate insiders own 4.30% of the company’s stock.

Several institutional investors have recently bought and sold shares of ALNY. FMR LLC grew its position in shares of Alnylam Pharmaceuticals by 6.3% during the 2nd quarter. FMR LLC now owns 13,723,153 shares of the biopharmaceutical company’s stock worth $1,094,559,000 after buying an additional 815,270 shares during the period. Vanguard Group Inc. grew its position in shares of Alnylam Pharmaceuticals by 13.4% during the 2nd quarter. Vanguard Group Inc. now owns 6,419,508 shares of the biopharmaceutical company’s stock worth $512,020,000 after buying an additional 759,295 shares during the period. Janus Henderson Group PLC acquired a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter worth about $53,226,000. Orbimed Advisors LLC grew its position in shares of Alnylam Pharmaceuticals by 69.7% during the 3rd quarter. Orbimed Advisors LLC now owns 1,084,800 shares of the biopharmaceutical company’s stock worth $127,453,000 after buying an additional 445,600 shares during the period. Finally, BlackRock Inc. grew its position in shares of Alnylam Pharmaceuticals by 9.3% during the 2nd quarter. BlackRock Inc. now owns 5,188,191 shares of the biopharmaceutical company’s stock worth $413,811,000 after buying an additional 441,957 shares during the period. Institutional investors own 88.39% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Jefferies Group Analysts Raise Earnings Estimates for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)” was originally published by BBNS and is the sole property of of BBNS. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://baseballnewssource.com/markets/fy2017-eps-estimates-for-alnylam-pharmaceuticals-inc-raised-by-jefferies-group-alny/1822470.html.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.